Compare AU
Compare CURE vs. U100
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and U100. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
CURE | U100 | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 135 |
Median incremental investment | $624.65 | $1,015.47 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,354.30 | $2,653.92 |
Average age group | > 35 | > 35 |
Key Summary
CURE | U100 | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | U100.AX was created on 2023-08-21 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 57.23m in AUM and 101 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Global X US 100 Index. |
Top 3 holdings | AbbVie Inc (2.62 %) Alnylam Pharmaceuticals Inc (2.59 %) Amgen Inc (2.59 %) | Global X Us 100 ETF. (100 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.45 % | 0.24 % |
Key Summary
CURE | U100 | |
|---|---|---|
Issuer | Global X | Global X |
Tracking index | S&P Biotechnology Select Industry | Global X US 100 Index - Benchmark TR Gross |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.24 % |
Price | $46.70 | $13.68 |
Size | $33.491 million | $56.071 million |
10Y return | N/A | N/A |
Annual distribution/ dividend yield (5Y) | 4.24 % | 0.06 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 22/08/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | U100 | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 79 | 135 |
Median incremental investment | $624.65 | $1,015.47 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,354.30 | $2,653.92 |
Average age group | > 35 | > 35 |
Pros and Cons
CURE | U100 | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | U100 |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |